CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeti
CG oncology announces the durability of the best disease in Bond-003 Cohort C and promising to early signal in crotostimogene Grenadenorepvec at the annual Meeti of the Urological Association
Report
English